Quantum computing enters the pharma arena with a new partnership between INmune Bio and Quantum Computing Inc. (QCi). The two companies are joining forces to apply QCi's Dirac-3S quantum optimization machine alongside AI and conventional data analytics to uncover new potential indications for XPro1595 — INmune Bio's investigational drug designed to selectively inhibit soluble tumor necrosis factor (TNF), a key driver of inflammation implicated in Alzheimer's and other diseases.

The collaboration will tap into INmune Bio's clinical datasets spanning four trials, plus publicly available biomedical data, to identify diseases that share the same underlying biology XPro targets. The team will prioritize rare diseases first, where smaller, faster trials are feasible and pediatric approvals could earn a Priority Review Voucher — a significant regulatory incentive.

Key Takeaways:

• XPro1595 selectively inhibits soluble TNF while preserving other immune functions, making it a targeted anti-inflammatory approach
• The partnership will benchmark quantum optimization against conventional machine-learning methods to determine where quantum adds the most value
• This is QCi's first commercial engagement in the pharmaceutical and biotech market

Why it matters: This collaboration signals a growing role for quantum computing in drug discovery — potentially accelerating the identification of new treatment targets and patient populations in ways traditional analytics can't match.